Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
WVE
Strong SellWave Life Sciences, Inc. · Healthcare · United States · $993M · Avg Vol: $15M/d
COMPANY DESCRIPTION
Wave Life Sciences Ltd. is a clinical-stage biotechnology company designing stereopure oligonucleotides to treat genetically defined diseases. The company's competitive moat is its proprietary PRISM platform, which enables the precise design of RNA-targeting therapeutics with optimized pharmacological properties. It operates as an innovative niche player in the precision genetic medicine sector.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.6M | 113.3M | 108.3M | 42.7M | 127.1% | 65.4M | 52.3M | 37.0M | -6.9% |
| EPS | -0.90 | -0.54 | -0.70 | -1.21 | — | -1.07 | -1.11 | -1.19 | — |
| Shares | 197.0M | 119.2M | 153.0M | 187.7M | -4.8% | 197.0M | — | — | — |
| Debt | 37.6M | 32.1M | 25.4M | 17.8M | -22.1% | 43.6M | — | — | — |
| Equity | -45.1M | 39.6M | 209.5M | 518.4M | 261.7% | — | — | — | — |
| Op CF | -127.8M | -19.4M | -151.0M | -187.5M | — | -191.6M | — | — | — |
| Inv CF | -1.3M | -1.1M | -0.9M | -0.7M | — | — | — | — | — |
| Fin CF | 67.2M | 132.5M | 253.9M | 488.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of WVE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| WVE | Wave Life Sciences, Inc.(you) | $993M | 2 | Strong Sell |
| OBX | Obsidian Therapeutics, Inc. | $1.0B | 5 | Strong Sell |
| OLMA | Olema Pharmaceuticals, Inc. | $899M | 5 | Strong Sell |
| ODTX | Odyssey Therapeutics, Inc. | $1.2B | 5 | Strong Sell |
| ATTO | Attovia Therapeutics, Inc. | $891M | 7 | Strong Sell |
| PROK | ProKidney Corp. | $731M | 4 | Strong Sell |
| SANA | Sana Biotechnology, Inc. | $1.2B | 8 | Strong Sell |
| ANNX | Annexon, Inc. | $942M | 10 | Strong Sell |
| PRME | Prime Medicine, Inc. | $655M | 2 | Strong Sell |
| CRVS | Corvus Pharmaceuticals, Inc. | $1.2B | 10 | Strong Sell |
Peer medians: ROE -25.6% · P/E 28.9x · Gross margin 58.7%